BC-CMLBlast Crisis of Chronic Myeloid Leukaemia
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Outcome of lymphoid BC-CML treated with dasatinib varies between 39 and 80% of hematologic remission and from 40 to 90% of any cytogenetic response [6,18,19].
Due to the low incidence of BC-CML, studies on the combination of TKIs with chemotherapy are rather scanty and usually with a limited number of enrolled patients.
Response to treatment is the most important prognostic factor for survival in BC-CML patients [24,25].
In conclusion, ponatinib monotherapy or in association with chemotherapy is a valid treatment option for non-HSCT eligible BC-CML patients and the only one available for those carrying the T315I mutation, which can develop during dasatinib therapy frequently.